Although we observed the enhanced anti-tumor effect after Tregs depletion during anti-PD-L1 treatment in mouse model, we also should be careful for the quickly use of this strategy in clinical cervical cancer patients. This evidence concerns the gene CD274 and cervical carcinoma.